Predictive Value of the Angiotensin-II type 1 and Endothelin Receptor Autoantibodies on disease course in COVID-19

Predictive Value of the Angiotensin-II type 1 and Endothelin Receptor Autoantibodies on disease course in COVID-19 - AERA-COVID

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49663

Enrollment

320

Registered

2021-01-14

Start date

2020-11-18

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronavirus COVID-19 pneumonia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients presenting at the Emergency department with respiratory symptoms and/or fever are evaluated for participation. In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Age >= 18 years - Hospitalized with PCR confirmed COVID-19 - Able to sign informed-consent form

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - the patients gives no informed consent - Already hospitalized for >72 hours

Design outcomes

Primary

Measure	Time frame
The proportion of patients with an unfavourable outcome in COVID-19.	—

Secondary

Measure	Time frame
To assess the presence of ANA antibodies in the study patients, and correlate their presence with ETAR and AT1R antibodies. To assess the presence and titre of AT1R and ETAR antibodies at admission and on the seventh day of admission for COVID-19 To assess cFN-EDA levels in COVID-19 patients at admission and on the seventh day of admission for COVID-19.	—

Countries

Netherlands

Outcome results